site stats

Laurikka-routti

WebLaurikka-Routti. LKT, naistentautien ja synnytysten erikoislääkäri. Asiakasarvio 9.7. 24kk keskiarvo, kun vastauksia yli 25 kpl. Siirry verkkoajanvaraukseen. Marjut Laurikka … WebThe progest in ST 1435, used parenterally for contraception or progestin therapy, had no adverse effects on serum lipids, blood pressure, or body weight, which are known to be risk factors for coronary artery disease. Objective: To study the changes in serum lipids, serum chemistry, blood pressure, and body weight in long-term users of subcutaneous …

Contraception with subdermal implants releasing the

Web1 Nov 1992 · Laurikka-Routti M 1. Author information. Affiliations. 1 author. 1. City Maternity Hospital, Helsinki, Finland. Obstetrics and Gynecology, 01 Nov 1992, 80(5): 855-859 … Web1 Dec 1992 · M. Laurikka-Routti, M. Haukkamaa Published 1 December 1992 Medicine Fertility and sterility View on PubMed doi.org Save to Library Create Alert Cite 17 … sql server find field in database https://maidaroma.com

Transdermal absorption of the progestin ST-1435 ... - Europe PMC

WebDOI: 10.1016/0010-7824(81)90115-3 Corpus ID: 72256207; Contraception with subcutaneous capsules containing ST-1435. Pituitary and ovarian function and plasma levels of ST-1435 Web1 Dec 1992 · Laurikka-Routti, M. Haukkamaa, O. Heikinheimo, A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipid and serum chemistry Contraception 42: (1990) 111-120 13. WebThese implants have been developed for contraception and they have a life-time of two years. Three implant lengths of 4, 6 and 8 cm were tested to find the optimal steroid dose … sql server find all indexes in database

Suppression of ovarian function with the transdermally

Category:Contraception with subdermal implants releasing the

Tags:Laurikka-routti

Laurikka-routti

Progesterone Review of Safety For Clinical Studies

Web1 Oct 1992 · M. Laurikka-Routti, M. Haukkamaa, O. Heikinheimo A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry Contraception, 42 ( 1990), pp. 111 - 120 View PDF View article View in Scopus Google Scholar 10. WebInt J Fertil 1976; 21: 103-8. 4. Laurikka-Routti M, Haukkamaa M, Lahteenmaki P. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435. Fertil Steril 1992; 58: 680-9. 5. Croxatto HB, Diaz S. The place of …

Laurikka-routti

Did you know?

Web1 Jan 1992 · M Laurikka-Routti, M Haukkamaa, O Heikinheimo A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: Bleeding control, serum steroid … WebSemantic Scholar extracted view of "Suppression of ovarian function with the transdermally given synthetic progestin ST 1435" by M. Laurikka-Routti et al. Skip to search form Skip …

Web8 Mar 2024 · Naistentautien ja synnytysten erikoislääkäri Marjut Laurikka-Routti sanoo, että kiusallisista vaihdevuosioireista ei kannata kärsiä, koska ne voidaan poistaa hormonihoidolla tehokkaasti. Aamutohtorin aiheena … WebPIP: Physicians inserted a new 4-cm subdermal implant releasing the progestin ST-1435 (78 mg) into the ventral area of the left upper arm in 26 healthy 20-36 year old women at the …

WebThese implants have been developed for contraception and they have a life-time of two years. Three implant lengths of 4, 6 and 8 cm were tested to find the optimal steroid dose for inhibition of ovulation. Serum samples were collected twice per week during a six-week period every six months. WebLaurikka-Routti, M., Haukkamaa, M., & Lähteenmäki, P. (1992). Suppression of ovarian-function with the transdermally given synthetic progestin ST 1435. Fertility and Sterility : …

Web393-408; Laurikka-Routti, Haukkamaa, A Contraceptive Subdermal Implant Releasing The Progestin ST-1435: Ova rian Function, Bleeding Patterns, And Side Effects”, Fertil ity and Sterility, “1992”, 58, 6, Pgs. 1142-1147. There have also been proposals for the construction of subcutaneous implantable male contraceptives. See

WebThe progest in ST 1435, used parenterally for contraception or progestin therapy, had no adverse effects on serum lipids, blood pressure, or body weight, which are known to be … sql server find deadlock extended eventWebLaurikka-Routti, Marjut ; Haukkamaa, Maija. / A contraceptive subdermal implant releasing the progestin ST-1435 - ovarian-function, bleeding patterns, and side-effects.Julkaisussa: Fertility and Sterility : official journal of the American Fertility Society . 1992 ; Vuosikerta 58.Sivut 1142-1147. sql server find login creation dateWeb1 Sep 1991 · Europe PMC is an archive of life sciences journal literature. sherk 1 online latino